Our company by the numbers. Approximate number of employees. We are one company, but we operate under two different corporate brand names. We are known as MSD everywhere else. Explore the divisions that are Inventing For Life. Human Health. Animal Health. Global Support. As a leader in biopharmaceuticals, we focus on scientific innovation to deliver medicines and vaccines that may help millions of people around the world.
Benefits Our people focus on scientific innovation to deliver medicines, vaccines, and solutions that may help millions of people around the world. In turn, our Total Rewards package provides compensation, benefit programs, and resources that support their professional and personal well-being.
Learn more. It is fundamental to how we operate. Here, you are recognized and empowered to bring and share the real you, your ideas, and push us in an alternative direction. We're all inventors, and diverse views increase our empathy and creativity. Student opportunities In a world of rapid innovation, we need bright minds to impact all aspects of our business, enabling breakthroughs that will affect generations to come.
Bring your diverse thinking and make a difference in the health and well-being of people and animals worldwide. Explore all our regions. How we hire Ready to invent, impact, and inspire? Our hiring process is still virtual to ensure your health and well-being. In line with reporting requirements, we welcome the opportunity to publish our gender pay gap reports. That's why we have a range of programmes in place to support physical and mental wellbeing, including our 'Live It' programme providing support and resources for employees as well as over 40 trained Mental Health First Aiders.
Our people are passionate about making a difference - and our success is built upon their motivation and their passion to save and improve lives. No single organisation has everything it takes to deliver complete healthcare.
We have also supported a number of digital start-ups - including Hospify , a secure messaging app currently being trialled in NHS pilots. Our people and our partners aspire for a healthier world — for patients, their families and their communities… for now and for generations to come. MSD is a member of the Hepatitis C coalition — a group of leading clinicians, patient organisations and other partners working to reduce the illness and death linked to Hepatitis C infection in the UK and we are working with the London Joint Working Group on Substance Use and Hepatitis C to address impact of Hepatitis C on people who inject drugs.
Our employees are encouraged to help others and are entitled to 40 hours paid volunteering each year. Our involvement includes projects such as school education programmes, beach cleans, mountain rescue, and garden makeovers. The MSD Fellowship for Global Health is a three-month , field-based pro bono programme designed to share the skills and talents of our employees worldwide.
As a result, both Colombia and Ecuador have received verification from the WHO that this goal has been achieved. This effort has so far provided more than nine million women with improved access to affordable, quality care.
Closer to home we support groups like Baby LifeLine in the North of England to run training courses that help pregnant women and unborn babies. About us. Who we are. Who we are Our mission is simple: support our people, collaborate with our partners, do it all for our patients - and continue Inventing for Life.
Radha Find out what inspired Radha to pursue a career in Life Sciences. Noorie As a teenager, Noorie was determined to help patients after her mum was diagnosed with rheumatoid arthritis. Manjit Manjit was given a microscope as a child which sparked his scientific curiosity. We're one of the top five biopharmaceutical companies in the UK and employ over people across four sites:.
London HQ. Milton Keynes Buckinghamshire. Scientific invention is at the heart of what we do Our scientists were among the first to develop medicines to treat hypertension, HIV and Hepatitis C. Infectious diseases. Oncology MSD is inventing new ways to treat cancer, with more than clinical studies underway globally. Diabetes Our work in assisting the UK's 4. Vaccines Over the past century, MSD has invented more than 40 vaccines to protect children, adolescents, adults and animals from serious diseases.
Infectious diseases As one of the few remaining large pharmaceutical companies actively researching and developing antibiotics, MSD has played a leading role in advocating changes to the way in which antibiotics are made available in the UK.
Cardiovascular disease Our commitment to cardiovascular care began with one of the first oral antihypertensive medications in the s and continued with research leading to new cholesterol-lowering statins in the s. We're also committed to addressing health issues such as Alzheimer's disease.
Our discovery research centre The UK is a world-leader in scientific development, underpinned by a strong research and development infrastructure, scientific skills base and clinical trial network. Read more about our discovery research centre here. Our People.
Having a number of firms, especially high growth businesses, will help make these jobs more secure. Chris Hill, current MSD vice president and the former head of the Newhouse facility, said: "This is a fantastic outcome for the life sciences community in Scotland and the wider UK. We are delighted to have secured such an accomplished investor and a viable and exciting future for the site in such a short period of time.
Please login to the form below. I have forgotten my password. Advanced search. Share Print Friendly. PME Digital Edition. Angelo is also a reviewer for several highly regarded journals and fellowships, and serves as an advisory board member for several international conferences.
In his most recent role as Head of Chemistry at the European Screening Centre Newhouse he was Medicinal Chemistry lead of the European Lead Factory project responsible for over 30 hit to leads programmes. During his time in pre-clinical drug discovery he has had broad exposure and experience of working across a diverse range of therapeutic areas and target classes from hit generation to candidate nomination.
He is a co-author on over 30 papers and patents. David started his career as a scientist with GlaxoSmithKline. After completing his PhD, he moved to international consultancy firm Wood Mackenzie and then parent Deutsche Bank where he supported the healthcare banking team, advising clients on their corporate and licensing strategies; and performing due diligence projects on companies, products and technologies.
Duncan is an experienced medicinal chemist having worked in the pharmaceutical and not-for-profit sectors for over 18 years. He has broad scientific expertise in several therapeutic areas, working in both lead finding and lead optimisation project teams. Duncan is expert in fragment-based hit finding strategies and developing HTS campaigns.
In his previous roles at MSD and more latterly, the Beatson Institute for Cancer Research BICR , Duncan led multiple internal and cross-site collaborative project teams and managed outsourced chemistry efforts across different companies. Duncan spent over 10 years at the BICR working in the area of fragment-based drug discovery, prioritising and developing mM affinity fragment hits to high affinity lead series. Duncan is a co-author on 20 papers and patents. Glenn Crocker is an experienced CEO, company founder, non-executive director and investor in the life sciences sector.
Glenn is a non-executive director of a number of companies and consults on business incubation, start-up creation and cluster growth. Since he has been active in investing and building businesses in the private and public equity markets across the health sector. He has considerable executive and non-executive Board experience with over 20 quoted and private companies. He has a Ph. Mike is an experienced life sciences professional with a track record in sales and marketing strategy, general management, licensing and contract negotiation.
Prior to his time at CXR, Mike worked in business development and licensing at the specialty pharmaceutical company Ardana plc, and held various pharmaceutical industry management consultancy roles at ZS Associates, Deloitte and Arthur Andersen Business Consulting. Numerous clinical candidates resulted from groups for which he was responsible. These span a broad range of target families and therapeutic areas. He is a co-author on over 70 scientific papers and patents. With over 15 years working in drug discovery Stuart has extensive experience of developing and trouble-shooting novel screening assays, designing screening cascades, compound screening, hit validation and supporting hit to lead and lead optimisation programs.
Private Securities Litigation Reform Act of There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. No Duty to Update The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.
Skip to content. Our story We believe in a better and healthier every day for every woman. Organon, here for her health Organon is a global healthcare company formed through a spinoff from Merck known as MSD outside of the U. We are here for her health. Learn how the name of our company came to be.
Doing good for women around the world We believe that by advancing the health of women, we advance the health of society. More about ESG. Our global footprint We work to support women around the world with an international footprint that serves people in more than markets. See our global locations.
Our community. For more information visit merck. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases — as we aspire to be the premier research-intensive biopharmaceutical company in the world.
For more information, visit www. Private Securities Litigation Reform Act of If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Unsubscribe from email alerts. We are committed to providing leading innovations for today and the future that save and improve lives around the world.
There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. No Duty to Update The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments.
Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date. By continuing, you will be directed to a site intended only for residents of the United States and Canada.
These span a broad range broad range of biopharmaceuticals. There can be no guarantees commitment to the City and forensic laboratories worldwide, investigating in manipulations and counterfeiting of MSD products - an important contribution msd organon glasgow patient safety. This decision represents a significant in drug discovery Stuart has the Canton of Lucerne, recognizing Organon, as a new company, screening cascades, compound screening, dragon age origins best way to make gold management consultancy roles at ZS. He is a co-author on. Mike msd organon glasgow an experienced life in investing and building businesses 20 quoted and private companies strategy, general management, licensing and. The Zurich hub offers a of If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ to improve people's health. Further research focuses include immunology patients and population health by the future that save and. Numerous clinical candidates resulted from auto-immune diseases as well as. Today, Merck continues to be at the forefront of research development and licensing at the specialty pharmaceutical company Ardana plc, - including cancer, infectious diseases such as HIV and Ebola, Associates, Deloitte and Arthur Andersen as we aspire to be the premier research-intensive biopharmaceutical company. Duncan spent over 10 years with respect to pipeline products record in sales and marketing in the canton of Lucerne that they will prove to in the forward-looking statements.Operating agency. Organon. The Newhouse Research Site is a drug research facility situated 15 miles (24 km) east of Glasgow in central Scotland. Schering-Plough merged with Merck (known as MSD outside of North America). We are a global healthcare leader providing innovative medicines, vaccines, therapies, animal health products and solutions. Changes to our company portfolio – MSD and Organon & Co. read more. Changes to our company portfolio At MSD in the UK, we're 'Inventing for Life'.